Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of intravenous edaravone (MCI-186) infusion regimen in acute ischemic stroke
2008-003397-17Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of edaravone in ischemic stroke (3 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Adverse events (safety and tolerability). Started Oct 2008; status: completed.
02
Drugs
edaravone
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2008-003397-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003397-17.